Welcome to our dedicated page for Oric Pharmaceuticals news (Ticker: ORIC), a resource for investors and traders seeking the latest updates and insights on Oric Pharmaceuticals stock.
Oric Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is dedicated to discovering and developing innovative therapies for the treatment of cancer. Headquartered in South San Francisco, California, Oric Pharmaceuticals was founded in 2014 and has since focused on addressing the challenging problem of cancer resistance to existing treatments.
The company's lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor. This receptor has been identified as a key player in the resistance mechanisms against various classes of cancer therapeutics, particularly across solid tumors. By targeting this receptor, ORIC-101 aims to enhance the effectiveness of existing cancer treatments.
Another significant asset in Oric's pipeline is ORIC-533, an orally bioavailable small molecule inhibitor of CD73. CD73 plays a role in resistance to both chemotherapy and immunotherapy, and ORIC-533 is being developed to counteract this resistance, offering a potential new avenue for treating patients who do not respond to current therapies.
In addition to ORIC-101 and ORIC-533, the company is also developing ORIC-944 and ORIC-114, each targeting different mechanisms of cancer resistance. ORIC-944 has shown promise in initial Phase 1b data, and the company has outlined several anticipated milestones for these programs in the near future.
Oric Pharmaceuticals demonstrates a robust commitment to advancing the field of precision oncology. The company leverages its expertise in hormone-dependent cancers, precision oncology, and key tumor dependencies to build a diverse pipeline of therapies. These efforts are supported by strategic partnerships and collaborations aimed at accelerating the development and commercialization of their treatment candidates.
Financially, Oric Pharmaceuticals has provided guidance and updates to keep stakeholders informed about their progress and strategic direction. For the latest news and developments, investors and interested parties are encouraged to stay tuned to the company's announcements.
Contact: Dominic Piscitelli, Chief Financial Officer
ORIC Pharmaceuticals, a clinical stage oncology company, announced that CFO Dominic Piscitelli will present at the H.C. Wainwright Global Investment Conference on May 24, 2022, at 7:00 a.m. ET. The presentation will focus on the company's innovative treatment strategies for overcoming resistance in cancer therapies. It will be pre-recorded and accessible via their investor website, with a replay available for 90 days post-event. ORIC's pipeline includes ORIC-533, ORIC-114, and ORIC-944, targeting various cancers and mechanisms of resistance.
ORIC Pharmaceuticals reported Q1 2022 financial results, with cash and investments totaling $256.2 million, sufficient to fund operations into 2H 2024. The company is advancing three Phase 1b oncology programs, expecting initial data in 1H 2023 for ORIC-533, ORIC-114, and ORIC-944. Research and development expenses rose to $16.8 million due to the advancement of its product pipeline. General and administrative expenses increased to $6.4 million. The net loss for the quarter stood at $23.2 million, with net loss per share at $0.59.
ORIC Pharmaceuticals presented significant preclinical data at the 2022 AACR Annual Meeting, showcasing its broad oncology pipeline. ORIC-533, a CD73 inhibitor, showed potential in multiple myeloma, while ORIC-114 demonstrated efficacy against EGFR/HER2 mutations in advanced solid tumors. The company also introduced novel PLK4 inhibitors targeting breast cancer. Initial clinical data for ORIC-533, ORIC-114, and ORIC-944 is anticipated in the first half of 2023, emphasizing their potential in overcoming therapeutic resistance.
ORIC Pharmaceuticals announced the discontinuation of the development of ORIC-101 due to insufficient clinical activity in Phase 1b studies. The company will redirect efforts toward advancing three ongoing single-agent Phase 1 programs: ORIC-533 for multiple myeloma, ORIC-114 for EGFR/HER2 cancers, and ORIC-944 for prostate cancer. With a cash balance of $280.4 million, the cash runway is projected to extend into the second half of 2024. Initial data from the three programs is expected in the first half of 2023.
ORIC Pharmaceuticals (Nasdaq: ORIC) will host a conference call and webcast on March 21, 2022, at 5:00 p.m. ET to discuss its fourth quarter and full year 2021 financial results. The event will provide an operational update on the company's efforts to develop therapies addressing cancer treatment resistance, particularly their lead product candidate, ORIC-101, currently in Phase 1b trials. Participants can join via a domestic or international call or through their website, with a replay available for 90 days.
ORIC Pharmaceuticals announced a series of presentations at the 2022 AACR Annual Meeting from April 8-13, 2022, in New Orleans, LA. Key highlights include:
- ORIC-533, a CD73 inhibitor, demonstrated potential in reversing immunosuppression in multiple myeloma patients.
- ORIC-114 showcased superior brain penetration and anti-tumor activity in NSCLC models.
- New PLK4 inhibitors revealed promising results targeting synthetic lethality in breast cancer.
These presentations underscore ORIC's commitment to addressing therapeutic resistance in oncology.
ORIC Pharmaceuticals announced participation in a virtual fireside chat at the Guggenheim 2022 Oncology Conference on February 10, 2022, at 2:00 p.m. ET. The event will focus on the company’s innovations in overcoming cancer therapeutic resistance. Investors can access a live webcast through the company's website, with a replay available for 90 days. ORIC’s lead candidate, ORIC-101, targets glucocorticoid receptor resistance across solid tumors and is currently in Phase 1b trials for prostate cancer and other solid tumors.
ORIC Pharmaceuticals (Nasdaq: ORIC) announced the clearance of its Clinical Trial Application for ORIC-114 in South Korea, focusing on treating cancers with EGFR and HER2 exon 20 insertion mutations. This marks the third regulatory clearance in eight months, highlighting ORIC's commitment to advancing its clinical portfolio. The company is set to initiate a Phase 1 study for ORIC-114, anticipating initial data in the first half of 2023. ORIC has enough cash to support its operations into 2024 and plans five clinical updates across four programs by mid-2023.
ORIC Pharmaceuticals recently announced updates on its clinical programs and upcoming milestones. The company is on track to provide data from its ongoing clinical trials in 2022 and 2023, including ORIC-101, ORIC-533, ORIC-114, and ORIC-944. ORIC holds approximately $280.8 million in cash and investments, projected to fund operations into early 2024. CEO Jacob M. Chacko highlighted the advancements made in 2021, such as IND submissions and strengthening the company’s financial position.
ORIC Pharmaceuticals announced that Dr. Jacob Chacko, CEO, will present at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 3:00 p.m. ET. The presentation can be accessed via the investor section of their website, with a replay available for 30 days post-event.
ORIC focuses on overcoming therapeutic resistance in cancer with key candidates including ORIC-101, in Phase 1b trials, and other products targeting various cancers. For more information, visit oricpharma.com.
FAQ
What is the current stock price of Oric Pharmaceuticals (ORIC)?
What is the market cap of Oric Pharmaceuticals (ORIC)?
What is Oric Pharmaceuticals, Inc.?
What is ORIC-101?
What is ORIC-533?
Where is Oric Pharmaceuticals headquartered?
When was Oric Pharmaceuticals founded?
What other products are in Oric Pharmaceuticals' pipeline?
What are the core areas of expertise for Oric Pharmaceuticals?
How can I contact Oric Pharmaceuticals for more information?
What is the company’s financial condition?
What recent achievements has Oric Pharmaceuticals made?
